LA Improves the Prognosis of Patients With ICVD
Trial statusNot yet recruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age35-65
SponsorHuaqiu Zhang
About this trial
Ischemic cerebrovascular disease will cause serious harm to the life and safety of patients, and the treatment prognosis is poor. Numerous clinical trials have demonstrated that probiotics can improve cognitive function in people under multimodal. We have previously found that Lactobacillus acidophilus administration could improve cognitive impairment in MCAO and BCAS mice. Therefore, Based on the above research background and the basis of previous studies, we believe that the administration of Lactobacillus acidophilus solid drink (pure Lactobacillus acidophilus strain) can improve the cognitive function of patients with cerebral ischemia through the "brain-gut axis".
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Between 35 and 65 years old;
Han nationality;
Diagnosed as ischemic cerebrovascular disease with mild to moderate symptoms;
Can communicate normally, complete neuropsychological tests independently, and sign informed consent;
Disqualifiers
previous dementia;
hearing or visual impairment;
Drugs that may or are known to influence cognitive abuse;
alcohol addiction;
Trial design
Design model
Parallel
Treatments tested in this trial
Lactobacillus acidophilus
Dietary supplementLactobacillus acidophilus solid drink (pure bacteria, food grade, JYLA-191, Shandong Zhongke Jia-yi Biological Engineering Co., LTD.), 3g (containing 2\*10\^10CFU), twice a day, once in the morning and once in the evening, 1 bag each time, by drinking water, direct oral intake, 1 month/course, continuous use for three courses.
Maltodextrin
Dietary supplementMaltodextrin solid drink (food grade, MD20, Shandong Zhongke Jia-yi Biological Engineering Co., LTD.), 3g, twice a day, once in the morning and once in the evening, 1 bag each time, by drinking water, direct oral intake, 1 month/course, continuous use for three courses.
Treatment groups
236 Participants
are divided into 2 treatment groupsGroup A: Control groupPlacebo comparator 1 intervention
Group B: LA treatment groupExperimental treatment 1 intervention
Trial outcomes
Primary outcomes
1
Mini-mental State Examination (MMSE, 0-30) scale
Higher scale scores mean better cognitive function.
Time frame
Three months.2
Montreal Cognitive Assessment (MoCA, 0-30) scale
Higher scale scores mean better cognitive function.
Time frame
Three months.Locations
Sponsors and contacts
Click on the lead sponsor to view all of their trials.
Huaqiu Zhang
Lead sponsor
Tongji Hospital
Sponsor institution
Source ClinicalTrials.gov
This trial is not recruiting at the moment. You can still explore other options: